Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Novos obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021
The medical spa model has proven particularly effective at normalizing GLP-1 use among demographics that might not otherwise have considered obesity medication
These insights support more informed conversations with your provider about whether sweetener optimization, medication trials, or combination approaches align with your genetic landscape
Zhang Z, et al
117 Beinaglutide Beinaglutide was the first original drug approved for the treatment of obesity in China and the third GLP-1 class reduction drug approved worldwide, and it represents a new treatment option for overweight and obese patients
US$ 22.48
US$ 26.19
US$ 27.38
US$ 20.77
US$ 24.24
US$ 24.70
US$ 22.31
